AI Article Synopsis
- The study compared the antifungal effectiveness of posaconazole, fluconazole, and amphotericin B against clinical yeast isolates.
- Posaconazole showed a significantly lower geometric mean Minimum Inhibitory Concentration (MIC) than fluconazole, indicating stronger antifungal activity, especially against fluconazole-resistant strains.
- These findings suggest that posaconazole could be a promising option for treating yeast infections.
Article Abstract
Objectives: The in vitro antifungal activity of posaconazole was compared with that of fluconazole and amphotericin B.
Materials And Methods: A microdilution method (M27-A2) was used with 331 clinical yeast isolates.
Results: The geometric mean MICs of posaconazole, fluconazole and amphotericin B were 0.16, 0.91 and 0.15 mg/L, respectively. Posaconazole was markedly more active than fluconazole and was active against 9/11 fluconazole-resistant Candida albicans, and five Candida glabrata had an MIC of posaconazole of 16 mg/L.
Conclusions: These data indicate that posaconazole is a potentially effective antifungal agent for the treatment of mycoses caused by yeasts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dki022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!